Rhumbline Advisers Biomea Fusion, Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q4 2024
A detailed history of Rhumbline Advisers transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 37,434 shares of BMEA stock, worth $157,971. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37,434
Previous 35,892
4.3%
Holding current value
$157,971
Previous $362,000
59.94%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding BMEA
# of Institutions
105Shares Held
17.9MCall Options Held
1.68MPut Options Held
410K-
Cormorant Asset Management, LP Boston, MA3.57MShares$15.1 Million2.53% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$9.89 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY2.11MShares$8.9 Million0.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.4MShares$5.9 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.38MShares$5.82 Million0.01% of portfolio
About Biomea Fusion, Inc.
- Ticker BMEA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,290,600
- Market Cap $124M
- Description
- Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...